A Prospective Post-Marketing Observational Study of Brivaracetam in People With Focal Epilepsy.
Rayan YanesJoel Neves BriardTang-Duc Jeremy NguyenMaya SultanemDang Khoa NguyenSteve Alex GibbsKristin IkedaJeffrey JirschColin Bruce JosephsonLysa Boisse LomaxVéronique CloutierMark R KeezerPublished in: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques (2023)
We evaluated the effectiveness and tolerability of brivaracetam (BRV), an adjunctive antiseizure medication, as a treatment for focal epilepsy in adults. In this prospective study, we enrolled 51 participants from 3 sites across Canada. At 6 months, 68% (26/38) of participants were still taking BRV, among whom 35% (8/23) attained seizure freedom and 48% (11/23) saw their seizure frequency reduced by over 50%. We did not measure any significant change in irritability, quality of life, depression, and anxiety while treated with BRV. Our findings suggest BRV is effective in reducing seizure frequency among adults with focal epilepsy.